jun 8, 2017 - FDA requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market based on its concern that the benefits of the drug may no longer outweigh its risks.
Added to timeline:
Date:
jun 8, 2017
Now
~ 9 years ago